Evidence-Based Management of Recurrent Vulvovaginal Candidiasis
نویسنده
چکیده
Vulvo-vaginal candidiasis (VVC) is a common infection among women. 5-8% of women with acute infection experience recurrent vulvo-vaginal candidiasis (RVVC). There is currently no gold standard treatment for RVVC. Although antifungal agents such as imidazoles have been successfully used as first-line treatment for acute VVC, the effectiveness of these medications is limited for RVVC, and various reasons have been postulated to contribute to this. Here, we discuss the clinical features and pathogenesis of RVVC, and its usual recommended treatment regimens as well as newer upcoming potential alternative therapies for this chronic condition.
منابع مشابه
Vulvovaginal Disease: An Evidence-Based Approach to Medical Management
Vulvovaginal discharge complaints are very common, accounting for more than 10 million U.S. office visits annually and countless phone contacts [1]. Annual medication costs for these complaints are estimated at more than $700 million, with about half this amount spent on overthe-counter (OTC) preparations [2]. The diagnosis of initial vulvovaginal discharge complaints is usually straightforward...
متن کاملImmune Deviation in Recurrent Vulvovaginal Candidiasis: Correlation with Iron Deficiency Anemia
Background: Iron Deficiency Anemia (IDA) has been controversially linked to IL-4 production in previous studies. A predominant Th1 response leads to resistance against recurrent vulvovaginal candidiasis (RVVC), whereas a Th2 response exacerbates the disease. Objective: To investigate the possible effect of iron deficiency on the host’s susceptibility to RVVC as a result of the Th1/Th2 cytokine ...
متن کاملHighly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented
BACKGROUND Available literature concerning the epidemiologic or clinical features of vulvovaginal candidiasis commonly reports that: 75% of women will experience an episode of vulvovaginal candidiasis in their lifetimes, 50% of whom will experience at least a second episode, and 5-10% of all women will experience recurrent vulvovaginal candidiasis (≥4 episodes/1 year). In this debate we traced ...
متن کاملبررسی اختلافات بین گونهای مخمرهای کاندیدا در پاسخ به درمان با فلوکونازول در عفونتهای ولوواژینال شایع و عودکننده
Background: Looking at the increased incidence of recurrent vulvovaginal candidiasis and refractory resulting from such non-albicans Candida species in recent decades, this study was performed aiming the use of rapid biochemical and molecular detection of drug-resistant Candida species in response to fluconazole in patients with vulvovaginal candidiasis and recurrent vulvovaginal candidiasis. ...
متن کاملRecurrent Vulvovaginal Candidiasis: Could It Be Related to Cell-Mediated Immunity Defect in Response to Candida Antigen?
Objective Recurrent vulvovaginal candidiasis (RVVC) is a common cause of morbidity affecting millions of women worldwide. Patients with RVVC are thought to have an underlying immunologic defect. This study has been established to evaluate cell mediated immunity defect in response to candida antigen in RVVC cases. MaterialsAndMethods Our cross sectional study was performed in 3 groups of RVVC pa...
متن کامل